US2022213167A1PendingUtilityA1
Engineered cells expressing anti-tumor t cell receptors and methods of use thereof
Est. expiryMay 3, 2039(~12.8 yrs left)· nominal 20-yr term from priority
A61K 40/4273A61K 40/32A61K 40/11C12N 5/0636C07K 2318/20C07K 14/7051A61P 35/00C12N 15/1037C40B 50/06C07K 16/2833C07K 2317/21C40B 40/02C07K 2317/34C07K 16/30C40B 40/08
45
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Provided herein are compositions comprising recombinant mammalian cells that express recombinant T cell receptors with specificity against gp100 peptide:MHC antigens. Also provided are therapeutic methods of using the recombinant mammalian cells as cell therapies against melanoma tumors.
Claims
exact text as granted — not AI-modified1 . A non-naturally occurring mammalian cell, comprising recombinant T cell receptor subunits SEQ ID 1 and SEQ ID 2, that specifically binds gp100 antigen HLA*A 02:01/gp100 (KTWGQYWQV).
2 . A non-naturally occurring mammalian cell, comprising recombinant T cell receptor subunits SEQ ID 3 and SEQ ID 4, that specifically binds gp100 antigen HLA*A 02:01/gp100 (KTWGQYWQV).
3 . A non-naturally occurring mammalian cell, comprising recombinant T cell receptor subunits SEQ ID 5 and SEQ ID 6, that specifically binds gp100 antigen HLA*A 02:01/gp100 (KTWGQYWQV).
4 . A non-naturally occurring mammalian cell, comprising recombinant T cell receptor subunits SEQ ID 7 and SEQ ID 8, that specifically binds gp100 antigen HLA*A 02:01/gp100 (KTWGQYWQV).
5 . A non-naturally occurring mammalian cell, comprising recombinant T cell receptor subunits SEQ ID 9 and SEQ ID 10, that specifically binds gp100 antigen HLA*A 02:01/gp100 (KTWGQYWQV).Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.